RecruitingNCT07461116

Adverse Effects of ATG/ALG Therapy in Aplastic Anemia

A Study on the Dynamics and Grading Criteria Construction of Adverse Reactions to ATG/ALG Therapy in Aplastic Anemia

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment

200 participants

Start Date

Feb 23, 2026

Study Type

OBSERVATIONAL

Conditions

Aplastic Anaemia

Summary

This prospective, single-center, observational cohort study aims to systematically observe and describe the clinical characteristics of adverse reactions in patients with aplastic anemia undergoing ATG (Anti-Thymocyte Globulin) /ALG (Anti-Lymphocyte Globulin) treatment, providing a data foundation for the development of relevant management strategies. This study plans to enroll 200 aplastic anemia patients undergoing ATG/ALG treatment

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ATG/ALG for people with aplastic anaemia. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGATG/ALG

Participants will receive ATG/ALG according to standard dosing protocols as per clinical guidelines. During treatment, we will monitor and document any adverse reactions, including their type, severity, duration, and any necessary interventions or changes in treatment plan.